MX2020005036A - Inhibidores de inmunoproteasoma. - Google Patents
Inhibidores de inmunoproteasoma.Info
- Publication number
- MX2020005036A MX2020005036A MX2020005036A MX2020005036A MX2020005036A MX 2020005036 A MX2020005036 A MX 2020005036A MX 2020005036 A MX2020005036 A MX 2020005036A MX 2020005036 A MX2020005036 A MX 2020005036A MX 2020005036 A MX2020005036 A MX 2020005036A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- immunoproteasome
- inhibitors
- immunoproteasome inhibitors
- immunoproteasomes
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 101001136986 Homo sapiens Proteasome subunit beta type-8 Proteins 0.000 abstract 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 abstract 1
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 abstract 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente descripción se proporcionan compuestos, tales como un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable de este, que son inhibidores de inmunoproteasoma (tales como LMP2 y LMP7). Los compuestos descritos en la presente descripción pueden ser útiles para el tratamiento de enfermedades tratables mediante la inhibición de inmunoproteasomas. En la presente descripción también se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762587375P | 2017-11-16 | 2017-11-16 | |
| PCT/US2018/061132 WO2019099576A1 (en) | 2017-11-16 | 2018-11-14 | Immunoproteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005036A true MX2020005036A (es) | 2020-08-17 |
Family
ID=64572584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005036A MX2020005036A (es) | 2017-11-16 | 2018-11-14 | Inhibidores de inmunoproteasoma. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230133165A1 (es) |
| EP (1) | EP3710457B1 (es) |
| JP (1) | JP7333321B2 (es) |
| KR (1) | KR102647050B1 (es) |
| CN (1) | CN111491939B (es) |
| AU (1) | AU2018369787B2 (es) |
| CA (1) | CA3080958A1 (es) |
| DK (1) | DK3710457T3 (es) |
| ES (1) | ES2928787T3 (es) |
| HR (1) | HRP20221292T1 (es) |
| HU (1) | HUE060020T2 (es) |
| LT (1) | LT3710457T (es) |
| MX (1) | MX2020005036A (es) |
| PL (1) | PL3710457T3 (es) |
| PT (1) | PT3710457T (es) |
| RS (1) | RS63666B1 (es) |
| SI (1) | SI3710457T1 (es) |
| WO (1) | WO2019099576A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110248949B (zh) | 2017-01-18 | 2023-02-17 | 普林斯匹亚生物制药公司 | 免疫蛋白酶体抑制剂 |
| EP3710458A1 (en) | 2017-11-16 | 2020-09-23 | Principia Biopharma Inc. | Immunoproteasome inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| IL111175A0 (en) * | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| MX2015000908A (es) * | 2012-07-20 | 2015-09-21 | Cleave Biosciences Inc | Pirimidinas fusionadas como inhibidores del complejo p97. |
| EP3157909B1 (en) | 2014-06-20 | 2021-04-07 | Principia Biopharma Inc. | Lmp7 inhibitors |
| AU2015327345B9 (en) | 2014-10-01 | 2020-06-18 | Merck Patent Gmbh | Boronic acid derivatives |
| CN110248949B (zh) * | 2017-01-18 | 2023-02-17 | 普林斯匹亚生物制药公司 | 免疫蛋白酶体抑制剂 |
-
2018
- 2018-11-14 US US16/764,199 patent/US20230133165A1/en active Pending
- 2018-11-14 RS RS20220964A patent/RS63666B1/sr unknown
- 2018-11-14 WO PCT/US2018/061132 patent/WO2019099576A1/en unknown
- 2018-11-14 CA CA3080958A patent/CA3080958A1/en active Pending
- 2018-11-14 DK DK18812554.6T patent/DK3710457T3/da active
- 2018-11-14 PL PL18812554.6T patent/PL3710457T3/pl unknown
- 2018-11-14 CN CN201880081600.1A patent/CN111491939B/zh active Active
- 2018-11-14 AU AU2018369787A patent/AU2018369787B2/en active Active
- 2018-11-14 KR KR1020207016763A patent/KR102647050B1/ko active IP Right Grant
- 2018-11-14 MX MX2020005036A patent/MX2020005036A/es unknown
- 2018-11-14 HU HUE18812554A patent/HUE060020T2/hu unknown
- 2018-11-14 LT LTEPPCT/US2018/061132T patent/LT3710457T/lt unknown
- 2018-11-14 HR HRP20221292TT patent/HRP20221292T1/hr unknown
- 2018-11-14 SI SI201830791T patent/SI3710457T1/sl unknown
- 2018-11-14 ES ES18812554T patent/ES2928787T3/es active Active
- 2018-11-14 EP EP18812554.6A patent/EP3710457B1/en active Active
- 2018-11-14 JP JP2020526979A patent/JP7333321B2/ja active Active
- 2018-11-14 PT PT188125546T patent/PT3710457T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3710457B1 (en) | 2022-08-03 |
| RS63666B1 (sr) | 2022-11-30 |
| AU2018369787A1 (en) | 2020-05-14 |
| JP2021503467A (ja) | 2021-02-12 |
| CN111491939A (zh) | 2020-08-04 |
| SI3710457T1 (sl) | 2023-02-28 |
| JP7333321B2 (ja) | 2023-08-24 |
| HRP20221292T1 (hr) | 2022-12-23 |
| EP3710457A1 (en) | 2020-09-23 |
| CA3080958A1 (en) | 2019-05-23 |
| DK3710457T3 (da) | 2022-10-24 |
| LT3710457T (lt) | 2022-11-10 |
| US20230133165A1 (en) | 2023-05-04 |
| HUE060020T2 (hu) | 2023-01-28 |
| ES2928787T3 (es) | 2022-11-22 |
| PL3710457T3 (pl) | 2023-02-20 |
| PT3710457T (pt) | 2022-10-25 |
| KR102647050B1 (ko) | 2024-03-14 |
| AU2018369787B2 (en) | 2023-04-20 |
| CN111491939B (zh) | 2023-12-26 |
| WO2019099576A1 (en) | 2019-05-23 |
| KR20200090810A (ko) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012825A (es) | Inhibidores de inmunoproteasoma. | |
| MY200608A (en) | Hiv inhibitor compounds | |
| BR112018070677A2 (pt) | inibidores de mcl-1 macrocíclicos para o tratamento de câncer | |
| PH12020550256A1 (en) | 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors | |
| SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
| PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| EA201650031A1 (ru) | Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1 | |
| AU2018231032A8 (en) | JAK inhibitors containing a 4-membered heterocyclic amide | |
| EA201890473A1 (ru) | Гетероарильные производные в качестве ингибиторов parp | |
| MX2019008436A (es) | Inhibidores del inmunoproteasoma. | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| MY194116A (en) | Pharmaceutical compounds | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
| WO2015195950A8 (en) | Lmp7 inhibitors | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k | |
| MX2020005036A (es) | Inhibidores de inmunoproteasoma. | |
| WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
| NZ727715A (en) | Novel heterocyclic compounds having prs enzyme inhibitory effect | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
| NZ735249A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer’s disease |